Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
MapLight turns off preclinical tap to fund schizophrenia drug
Despite mixed results for its experimental schizophrenia treatment, MapLight is going all-in on the asset—at the expense of its preclinical programs.
James Waldron
Aug 14, 2026 4:38am
BioVie stock halves on Parkinson’s phase 2 readout
Aug 6, 2026 9:40am
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Jun 9, 2026 5:22am
Novartis ‘always looking’ for new ways to shuttle drugs to brain
May 28, 2026 8:44am
Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop
May 22, 2026 6:12am
Herantis taps Indivi for digital biomarker tech in new trial
May 19, 2026 7:45am
